Cargando…

Permanent interstitial (125)I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment

BACKGROUND: The management of pediatric recurrent or metastatic soft tissue sarcoma after multimodal treatment remains challenging. We investigated the feasibility, efficacy, and morbidity of permanent interstitial (125)I seed implantation under image guidance as a salvage treatment for pediatric pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Lihong, Wang, Junjie, Jiang, Yuliang, Li, Jinna, Lin, Lei, Ran, Weiqiang, Liu, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678721/
https://www.ncbi.nlm.nih.gov/pubmed/26666635
http://dx.doi.org/10.1186/s12957-015-0747-7
_version_ 1782405496355946496
author Yao, Lihong
Wang, Junjie
Jiang, Yuliang
Li, Jinna
Lin, Lei
Ran, Weiqiang
Liu, Chen
author_facet Yao, Lihong
Wang, Junjie
Jiang, Yuliang
Li, Jinna
Lin, Lei
Ran, Weiqiang
Liu, Chen
author_sort Yao, Lihong
collection PubMed
description BACKGROUND: The management of pediatric recurrent or metastatic soft tissue sarcoma after multimodal treatment remains challenging. We investigated the feasibility, efficacy, and morbidity of permanent interstitial (125)I seed implantation under image guidance as a salvage treatment for pediatric patients with recurrent or metastatic soft tissue sarcoma. METHODS: This was a retrospective study of 10 patients who underwent percutaneous ultrasound or computed tomography (CT) guided permanent (125)I seed implantation. Postoperative dosimetry was performed for all patients. Actuarial D90 was 121–187.1 Gy (median, 170.3 Gy). The number of (125)I seeds implanted was 6–158 (median, 34.5), with a median specific activity of 0.7 mCi per seed (range, 0.62–0.8 mCi); total activity was 4.2–113.76 mCi. Follow-up time was 6–107 months (median, 27.5 months); no patients were lost to follow-up. RESULTS: The overall response rate (complete response + partial response) was 8/10 (80 %), including two patients with complete response (CR) (20 %) and five patients with partial response (PR) (60 %). Local control rates after 1 and 2 years were 70.1 and 62.3 %, respectively, with a mean local control time of 70.6 months (95 % confidence interval (CI) 45.1–96.0). Survival rates after 1 and 2 years were 68.6 and 57.1 %, respectively, with a mean survival time of 65.3 months (95 % CI 34.1–96.5). Three patients died from distant metastasis; one died from local recurrence 12 months after seed implantation. Three patients suffered a grade I skin reaction and one developed ulceration. No severe adverse neurologic sequelae or blood vessel damage occurred. CONCLUSIONS: Image guided permanent interstitial (125)I seed implantation as a salvage treatment appears to have a satisfactory outcome in children with recurrent or metastatic soft tissue sarcoma.
format Online
Article
Text
id pubmed-4678721
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46787212015-12-16 Permanent interstitial (125)I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment Yao, Lihong Wang, Junjie Jiang, Yuliang Li, Jinna Lin, Lei Ran, Weiqiang Liu, Chen World J Surg Oncol Research BACKGROUND: The management of pediatric recurrent or metastatic soft tissue sarcoma after multimodal treatment remains challenging. We investigated the feasibility, efficacy, and morbidity of permanent interstitial (125)I seed implantation under image guidance as a salvage treatment for pediatric patients with recurrent or metastatic soft tissue sarcoma. METHODS: This was a retrospective study of 10 patients who underwent percutaneous ultrasound or computed tomography (CT) guided permanent (125)I seed implantation. Postoperative dosimetry was performed for all patients. Actuarial D90 was 121–187.1 Gy (median, 170.3 Gy). The number of (125)I seeds implanted was 6–158 (median, 34.5), with a median specific activity of 0.7 mCi per seed (range, 0.62–0.8 mCi); total activity was 4.2–113.76 mCi. Follow-up time was 6–107 months (median, 27.5 months); no patients were lost to follow-up. RESULTS: The overall response rate (complete response + partial response) was 8/10 (80 %), including two patients with complete response (CR) (20 %) and five patients with partial response (PR) (60 %). Local control rates after 1 and 2 years were 70.1 and 62.3 %, respectively, with a mean local control time of 70.6 months (95 % confidence interval (CI) 45.1–96.0). Survival rates after 1 and 2 years were 68.6 and 57.1 %, respectively, with a mean survival time of 65.3 months (95 % CI 34.1–96.5). Three patients died from distant metastasis; one died from local recurrence 12 months after seed implantation. Three patients suffered a grade I skin reaction and one developed ulceration. No severe adverse neurologic sequelae or blood vessel damage occurred. CONCLUSIONS: Image guided permanent interstitial (125)I seed implantation as a salvage treatment appears to have a satisfactory outcome in children with recurrent or metastatic soft tissue sarcoma. BioMed Central 2015-12-15 /pmc/articles/PMC4678721/ /pubmed/26666635 http://dx.doi.org/10.1186/s12957-015-0747-7 Text en © Yao et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yao, Lihong
Wang, Junjie
Jiang, Yuliang
Li, Jinna
Lin, Lei
Ran, Weiqiang
Liu, Chen
Permanent interstitial (125)I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment
title Permanent interstitial (125)I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment
title_full Permanent interstitial (125)I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment
title_fullStr Permanent interstitial (125)I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment
title_full_unstemmed Permanent interstitial (125)I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment
title_short Permanent interstitial (125)I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment
title_sort permanent interstitial (125)i seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678721/
https://www.ncbi.nlm.nih.gov/pubmed/26666635
http://dx.doi.org/10.1186/s12957-015-0747-7
work_keys_str_mv AT yaolihong permanentinterstitial125iseedimplantationasasalvagetherapyforpediatricrecurrentormetastaticsofttissuesarcomaaftermultidisciplinarytreatment
AT wangjunjie permanentinterstitial125iseedimplantationasasalvagetherapyforpediatricrecurrentormetastaticsofttissuesarcomaaftermultidisciplinarytreatment
AT jiangyuliang permanentinterstitial125iseedimplantationasasalvagetherapyforpediatricrecurrentormetastaticsofttissuesarcomaaftermultidisciplinarytreatment
AT lijinna permanentinterstitial125iseedimplantationasasalvagetherapyforpediatricrecurrentormetastaticsofttissuesarcomaaftermultidisciplinarytreatment
AT linlei permanentinterstitial125iseedimplantationasasalvagetherapyforpediatricrecurrentormetastaticsofttissuesarcomaaftermultidisciplinarytreatment
AT ranweiqiang permanentinterstitial125iseedimplantationasasalvagetherapyforpediatricrecurrentormetastaticsofttissuesarcomaaftermultidisciplinarytreatment
AT liuchen permanentinterstitial125iseedimplantationasasalvagetherapyforpediatricrecurrentormetastaticsofttissuesarcomaaftermultidisciplinarytreatment